27 -11 (49) 2022 — Zufarov P.S., Karimov M.M., — THE SIGNIFICANCE OF PROKINETICS IN THE THERAPY OF GASTROESOPHAGEAL REFLUX DISEASE IN COMORBIDITY WITH FUNCTIONAL DYSPEPSIA

THE SIGNIFICANCE OF PROKINETICS IN THE THERAPY OF GASTROESOPHAGEAL REFLUX DISEASE IN COMORBIDITY WITH FUNCTIONAL DYSPEPSIA

Zufarov P.S., Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Tashkent Medical Academy, Tashkent, Uzbekistan

Karimov M.M., Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Tashkent Medical Academy, Tashkent, Uzbekistan

Pulatova N.I, Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Tashkent Medical Academy, Tashkent, Uzbekistan

Saidova Sh.A., Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Tashkent Medical Academy, Tashkent, Uzbekistan

Pulatova D.B., Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Tashkent Medical Academy, Tashkent, Uzbekistan

Akbarova D.S. Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Tashkent Medical Academy, Tashkent, Uzbekistan

Resume

It has been shown that in patients with GERD and functional dyspepsia, the use of proton pump inhibitors leads to a decrease in heartburn and pain behind the sternum. However, symptoms such as regurgitation, belching, feeling of early satiety and heaviness after eating were stopped ineffectively. The inclusion in the treatment complex of the prokinetic domperidone at a dose of 10 mg 3 times a day contributed to a more effective regression of symptoms of impaired motility of the esophagus and stomach.

Keywords: gastroesophageal reflux disease, functional dyspepsia, proton pump inhibitors, prokinetics.

First page

152

Last page

157

For citation:Zufarov P.S., Karimov M.M., Pulatova N.I, Saidova Sh.A., Pulatova D.B., Akbarova D.S. THE SIGNIFICANCE OF PROKINETICS IN THE THERAPY OF GASTROESOPHAGEAL REFLUX DISEASE IN COMORBIDITY WITH FUNCTIONAL DYSPEPSIA //New Day in Medicine 11(49)2022 152-157 https://clck.ru/32iDXh

LIST OF REFERENCES:

1. De Bortoli N., Martinucci I., Bellini M., Savarino E. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. // World J Gastroenterol. 2013; 19(35):5787-97.
2. Domperidone IN.D. Packet [Электронный ресурс] // US Food and Drug Administration. 2018. 17 p. UPLhttps: //www.fda.gov/ downloads/drugs/ developmentapprovalprocess/ howdrugsaredevelopedandapproved/appro).
3. Drossman D. Rome III: The functional gastrointestinal disorders. – 3rd ed. – McLean, VA: Degnon Associates, Inc., 2006. – P. 369–418.
4. Keohane J., Quigley E.M. Functional dyspepsia and nonerosivereflux disease: clinical interactions and their implications. / MedGenMed. 2007;9(3):31.
5. Ortiz A., Cooper C.J., Alvarez A. Cardiovascular Safety Profile and Clinical Experience with High-Dose Domperidone Therapy for Nausea and Vomiting // Am. J.Med. Sci. 2015. Vol. 349 (5). P. 421–424.
6. Parkman H.P., Jacobs M.R., Mishra A. Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects Digestive Diseases and Sciences // Dig. Dis. Sci. 2011. Vol. 56 (1). P. 115–124.
7. Schey R., Saadi M., Midani D. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort // Dig. Dis. Sci. 2016. Vol. 61(12). P. 3545–3551.
8. Wolfe M.M., Lowe R.C. Investing in the Future of GERD // J. Clin. Gastroenterol. – 2007. – Vol. 41. – P. 209.
9. Yuan Y., Hunt R.H. Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? // Am. J. Gastroenterol. – 2008. – Vol. 103 (suppl 1). – P. 50. Abstract #128.